RESUMO
The role of urogenical infection in males in present-day urology is demonstrated with a focus on fluoroquinolones efficacy in combined treatment of urogenital infection. The mechanism of action, pharmacokinetics, the spectrum of antimicrobial activity of a novel fluoroquinolone drug avelox are detailed. Avelox use in combined therapy of mono- and mixed infections caused by ureaplasmas, chlamidias, mycoplasms is illustrated by original experience of the authors. Avelox is well tolerated and safe.
Assuntos
Anti-Infecciosos/uso terapêutico , Compostos Aza/uso terapêutico , Quinolinas/uso terapêutico , Uretrite/tratamento farmacológico , Infecções Urinárias/tratamento farmacológico , Adolescente , Adulto , Idoso , Fluoroquinolonas , Humanos , Masculino , Pessoa de Meia-Idade , Moxifloxacina , Resultado do Tratamento , Uretrite/microbiologia , Uretrite/parasitologiaRESUMO
The aim of the study was to validate clinical methodology on application of shock-wave impact on plaques in Peyronie's disease (PD). We studied short- and long-term results of extracorporeal shock-wave therapy (ESWT) in 54 patients 3, 6 and 12 months after the exposure. We performed ESWT sessions on different lithotriptors using different mechanisms of shock wave mechanism (hydromechanical and piezoelectric). Choice of the ESWT technique was based on the thickness and density of the plaque. The proposed ESWT method provides an effective treatment of the disease basing on the initial angle of penis deformation in erection.
